Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366355 | 0.87 | MEN1 (0.41) | MEN1KMT2ARECQLMTNR1AMTNR1B | |
| SCHEMBL8179403 | 0.82 | MEN1 (0.37) | TLR2MEN1KMT2ARECQLMTNR1A | |
| SCHEMBL29010635 | 0.81 | TSHR (0.43) | TLR2MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL5666064 | 0.80 | MEN1 (0.37) | MEN1KMT2ARECQLMTNR1AMTNR1B | |
| SCHEMBL2296514 | 0.80 | PHF8 (0.42) | MEN1KMT2ARECQLALDH1A1KDM4E | |
| SCHEMBL6924528 | 0.78 | RECQL (0.42) | MEN1KMT2ARECQLHPGDGAA | |
| SCHEMBL5572803 | 0.78 | TSHR (0.41) | TLR2MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL5572365 | 0.77 | TSHR (0.56) | MEN1KMT2ARECQLALDH1A1HPGD | |
| SCHEMBL18373774 | 0.77 | FAAH (0.55) | MEN1KMT2ARECQLMAPK1 | |
| SCHEMBL19953940 | 0.77 | HPGD (0.51) | TLR2MMP2KMT2ARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475257-B1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | BIOSTATUS LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| EP-3475257-B1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | BIOSTATUS LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-11447638-B2 | Acetalanthraquinone derivatives useful for cellular staining | BIOSTATUS LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| US-11447638-B2 | Acetalanthraquinone derivatives useful for cellular staining | BIOSTATUS LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| US-20190249011-A1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | BIOSTATUS LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190249011-A1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | BIOSTATUS LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3475257-A1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | Biostatus Limited (GB) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220969-A1 | ACETALANTHRAQUINONE DERIVATIVES USEFUL FOR CELLULAR STAINING | BIOSTATUS LIMITED (GB) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447638-B2 | Acetalanthraquinone derivatives useful for cellular staining | ERH, NR2E3, NR0B2 | TLR2 717/4885MMP2 1883/4885MEN1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.